Objective: To identify geographic areas in New York City (NYC) for implementing programming focused on reducing the burden attributed to poor glycemic control and improving the health of New Yorkers.
Design: We geocoded addresses of NYC residents in the NYC Hemoglobin A1c (HbA1C) Registry with high (>9%) HbA1c test values from 2011 to 2013 on an NYC base map. The ArcGIS point density spatial analysis tool was applied to create a map of NYC residents with diabetes in poor glycemic control.
Setting: The setting for HbA1c testing was medical facilities within NYC.
Participants: The study population included NYC residents (excluding undomiciled persons and addresses corresponding to prisons, hospitals, or nursing homes) 18 years or older who underwent HbA1c testing from 2011 to 2013.
Main Outcome Measures: A map depicting point density of NYC residents with poor glycemic control was developed each year from 2011 to 2013 (2011: n = 70 359; 2012: n = 75 643; 2013: n = 78 694).
Results: Particularly, high densities of persons in poor glycemic control were identified in Flatbush, East Harlem, Washington Heights/Inwood, and the South Bronx. The 2 highest-density gradients (out of 9) covered approximately 1.7% of the total habitable area in NYC, while accounting for more than 1 in 10 (10.5%) persons in poor glycemic control. The 3 highest-density gradients covered 4.1% of NYC's habitable area and accounted for more than 1 in 5 (21.9%) persons in poor glycemic control.
Conclusion: The point density analysis highlighted several defined geographic areas representing a meaningful proportion of the population in poor glycemic control. This analysis could be used to raise community awareness and guide potential programming focused on reducing the burden of poor glycemic control such as the placement of diabetes self-management education classes, community health workers, and farmers' markets. Given the geographic breadth of NYC and limited resources, focused efforts on these defined areas would reach a sizeable number of the at-risk population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/PHH.0000000000000544 | DOI Listing |
Prim Care Diabetes
December 2024
Endocrinology and Nutrition Service, Santa Creu i Sant Pau Hospital, Autonomous University of Barcelona, Barcelona, Spain; Biomedical Research Networking Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), Carlos III Health Institute (ISCIII), Barcelona, Spain; Spanish Diabetes Society, Former President, Spain.
Aims: To analyze glycemic and bodyweight control in people with type 2 diabetes mellitus (T2DM), and prescribing patterns in primary care.
Methods: We reviewed the electronic medical records of 5009 randomly selected T2DM patients, from 70 health centers in Spain. We analyzed results by age group and presence/absence of obesity.
Sci Rep
December 2024
Department of Pediatrics and Child Health Nursing, College of Medicine and Health Sciences, Injibara University, Injibara, Ethiopia.
Excessive daytime sleepiness is a common finding among type 2 diabetes mellitus patients. However there is scarce data that shows the magnitude of excessive daytime sleepiness, & its association with type 2 diabetes mellitus. Hence, the study aimed to assess the prevalence of excessive daytime sleepiness and its associated factors among type 2 diabetes mellitus patients at Wolkite University Specialized Hospital.
View Article and Find Full Text PDFFront Cardiovasc Med
December 2024
Department of Cardiovascular Medicine, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Objective: This study compared the value of different systemic immune-inflammatory markers for evaluating coronary collateralization (CC) in patients with type 2 diabetes mellitus (T2DM) and chronic total occlusion (CTO).
Methods: Systemic immune-inflammation index (SII), systemic inflammation response index (SIRI) and pan-immune-inflammation value (PIV) were calculated at admission in 1409 T2DM patients with CTO. The degree of coronary collaterals was estimated using the Rentrop scoring system and categorized into poor (Rentrop score 0 or 1) or good (Rentrop score 2 or 3) CC.
Cureus
November 2024
Department C, National Institute of Nutrition of Tunis, Tunis, TUN.
Type 1 diabetes mellitus (T1DM) is a common autoimmune pathology requiring lifelong insulin therapy. We report the case of a 12-year-old girl with T1DM admitted to Department C of the National Institute of Nutrition of Tunis for diabetic ketosis. She had suffered from T1DM for five years, with poor glycemic control (hemoglobin A1C = 10%) and poor therapeutic adherence.
View Article and Find Full Text PDFMicrovasc Res
December 2024
Department of Medical Laboratory Science, College of Health Sciences, Woldia University, P.O. box 400, Woldia, Ethiopia; Research Center for Tuberculosis and Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Prinshof, 0084 Pretoria, South Africa.
Background: Diabetes mellitus (DM) is a metabolic abnormality affecting 537 million people worldwide. Poor glycemic control, longer duration, and poor medication adherence increased the risk of DM complications. Comprehensive evidence on the pooled prevalence of microvascular complications in DM patients in Ethiopia is not available.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!